Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:2224 |
Name | essential thrombocythemia |
Definition | A myeloproliferative neoplasm that is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage and that results_in the overproduction of platelets. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer myeloid neoplasm myeloproliferative neoplasm essential thrombocythemia |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
JAK2 V617F | BMS-911543 | essential thrombocythemia | sensitive | detail... |
TP53 mutant | N/A | essential thrombocythemia | not applicable | detail... |
IDH2 mutant | N/A | essential thrombocythemia | not applicable | detail... |
JAK2 V617F | INCB053914 | essential thrombocythemia | predicted - sensitive | detail... |
JAK2 mutant | N/A | essential thrombocythemia | not applicable | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03065400 | Phase II | Pembrolizumab | PD-1 Inhibition in Advanced Myeloproliferative Neoplasms | Completed | USA | 0 |
NCT03123588 | Phase II | Ruxolitinib Anagrelide | Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) | Terminated | USA | 0 |
NCT03289910 | Phase II | Carboplatin + Topotecan + Veliparib Carboplatin + Topotecan | Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia | Active, not recruiting | USA | 0 |
NCT03862157 | Phase Ib/II | Azacitidine + MLN4924 + Venetoclax | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT04041050 | Phase I | Navitoclax Navitoclax + Ruxolitinib | A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | Active, not recruiting | USA | TUR | SWE | ITA | HRV | GBR | FRA | ESP | DEU | BGR | BEL | 3 |
NCT04262141 | Phase II | IMG-7289 | IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) | Active, not recruiting | USA | 0 |
NCT04282187 | Phase II | Decitabine + Fedratinib Decitabine + Ruxolitinib | Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | Recruiting | USA | 0 |
NCT04644211 | Phase II | Ruxolitinib | Ruxolitinib in Thrombocythemia and Polycythemia Vera | Recruiting | USA | 0 |
NCT04955938 | Phase I | Enasidenib + Fedratinib Fedratinib + Ivosidenib | A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms | Withdrawn | USA | 0 |
NCT05936359 | Phase I | INCA033989 INCA033989 + Ruxolitinib | A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | Recruiting | ITA | GBR | FRA | ESP | DNK | DEU | CAN | AUS | 1 |
NCT06034002 | Phase I | INCA033989 | A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms | Recruiting | USA | 0 |
NCT06150157 | Phase I | JNJ-88549968 | A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms | Recruiting | USA | GBR | FRA | ESP | DEU | CAN | 0 |
NCT06218628 | Phase I | Pacritinib + Talazoparib | Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition | Recruiting | USA | 0 |
NCT06291987 | Phase I | Ivosidenib + Ruxolitinib | Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation (MPN) | Recruiting | USA | 0 |
NCT06343805 | Phase I | AJ1-11095 | A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i) | Recruiting | USA | 0 |
NCT06351631 | Phase III | IMG-7289 | A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) | Recruiting | USA | NZL | ITA | GBR | AUS | 1 |